How Tobacco Turned Nicotine Into an Addiction Machine, Part 1 of 2

For years, the public was sold a story that now seems almost impossible to believe. Cigarettes were marketed as sophisticated, calming, and socially normal. The health risks were minimized, the messaging was polished, and the addiction problem was not yet being spoken about with the clarity it demanded. Then the science began to catch up with the marketing. On January 11, 1964, the Surgeon General of the U.S. Public Health Service released “Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service.”[1] That report marked a historic turning point in public understanding. But by the time the government began formally warning the public, one critical fact was already becoming impossible to ignore: the real engine of the cigarette business was nicotine.

That distinction matters because nicotine is not some side issue in the tobacco story. It is the center of it. The modern scientific consensus is direct. “Nicotine is the drug in tobacco that causes addiction.”[2] That line is devastating in its simplicity. It means the most commercially important part of the cigarette was never just the tobacco leaf, the paper, the branding, or the ritual. It was the drug effect that kept users coming back.

The federal government finally moved in 1965. Under the Federal Cigarette Labeling and Advertising Act of 1965, cigarette packages were required to carry this warning: “Caution: Cigarette Smoking May Be Hazardous to Your Health.”[3] The warning was historic, but it was also late. By then, cigarette use was already deeply embedded in daily life, and millions of smokers had already become dependent on nicotine. In other words, the label arrived after the habit had become a chemically reinforced cycle.

This is where the tobacco story becomes more disturbing.

The issue was not merely that tobacco companies sold a risky product while public understanding lagged behind. The deeper issue is that industry evidence later showed companies understood the addictive role of nicotine while publicly resisting that reality. One of the most widely cited internal tobacco industry statements, from 1963, put it with stunning bluntness: “We are, then, in the business of selling nicotine, an addictive drug.”[4] That sentence deserves to be read twice. It strips away the marketing language and exposes the underlying business model in plain English.

Nicotine itself occurs naturally in tobacco. That part is true. But that does not mean the cigarette remained some simple agricultural product. Over time, cigarette makers learned how to engineer product design, smoke chemistry, and delivery characteristics in ways that could intensify the impact of nicotine and reinforce dependence. The science on that point is not vague. The Surgeon General’s report on nicotine addiction states that “tobacco delivered nicotine is substantially more addictive than are pure nicotine forms” and adds that “other tobacco constituents, delivery methods, and processes may play a critical supporting role.”[2] That is not a minor detail. It is the difference between a plant containing nicotine and an industrial product designed to deliver it effectively, repeatedly, and habitually.

This is why the cigarette should not be understood merely as a tobacco product. It became, in practical terms, a delivery system. The National Cancer Institute has described the industry’s conduct in similarly serious terms, including the intentional design of cigarettes to ensure “optimum nicotine delivery.”[5] Once that is understood, the rest of the history begins to look less like consumer choice and more like dependency economics.

And that is the point many cessation products still fail to confront.

For decades, the dominant quit smoking category has largely been built around nicotine replacement. Gum, patches, and lozenges have all operated on the same underlying premise: continue supplying nicotine, but do it in a different format and hope the user gradually exits the cycle. That approach has helped some people, but the logic itself contains an obvious weakness. If nicotine is the drug that causes addiction, then continuing to feed nicotine into the body may preserve part of the very loop that needs to be broken.[2]

That is why the next stage of the category may look fundamentally different from the last 40 years.

The larger market is already moving in that direction. The CDC states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States” and that cigarette smoking “kills more than 480,000 Americans each year.”[6] Globally, the World Health Organization reports that tobacco “kills more than 8 million people each year.”[7] These are not stale legacy numbers from a problem that has passed. They are evidence of an ongoing public health crisis. The problem did not disappear. It simply evolved.

That evolution is exactly why nicotine itself has to be treated as the enemy.

If the original mistake was believing cigarettes were harmless, the second mistake was believing the problem could be fully solved while nicotine remained at the center of the solution. A more forward looking model is one that aims to help smokers move beyond nicotine entirely rather than continue rotating around it in new forms. That is where Redwood Scientific Technologies is positioning its development strategy. Through TBX FREE and TBX VAPE FREE, Redwood is advancing nicotine free oral thin film platforms designed to align with a broader shift in thinking: the objective is not merely to change the format of nicotine consumption, but to support the transition away from nicotine dependence itself. That positioning does not represent a claim of clinical outcome. It reflects alignment with the actual structure of the problem as science and public health now understand it.

This first part of the story matters because it explains how the trap was built. The public was late to the truth. The warning label was late to the truth. But the addiction mechanism was there early, and it was powerful. Once nicotine dependence became the commercial foundation of the category, the entire business model changed. Cigarettes were no longer just sold. They were optimized.

That history leads directly into Part 2.

Because once the public began to understand the danger of cigarettes more clearly, the nicotine economy did not vanish. It adapted. It modernized. And it found a new delivery system.

In Part 2, we examine how vaping became the next chapter in the same nicotine story, how the form changed while the dependency remained, and why the fight is no longer just against smoking. It is against nicotine itself.

Sources and References

[1] GovInfo, Anniversary of the Surgeon General’s First Report on Smoking and Health. “On January 11, 1964, the Surgeon General of the U.S. Public Health Service released ‘Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service.’”

[2] National Center for Biotechnology Information, How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking Attributable Disease. “Nicotine is the drug in tobacco that causes addiction.” Also: “tobacco delivered nicotine is substantially more addictive than are pure nicotine forms.”

[3] GovInfo, Federal Cigarette Labeling and Advertising Act of 1965. “Caution: Cigarette Smoking May Be Hazardous to Your Health.”

[4] Brown and Williamson document as discussed in peer reviewed literature. “We are, then, in the business of selling nicotine, an addictive drug.”

[5] National Cancer Institute, Monograph reference noting intentional cigarette design for “optimum nicotine delivery.”

[6] U.S. Centers for Disease Control and Prevention. “Cigarette smoking remains the leading cause of preventable disease and death in the United States.” Also: “Cigarette smoking kills more than 480,000 Americans each year.”

[7] World Health Organization. Tobacco “kills more than 8 million people each year.”

About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com

Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.

Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.